Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26".
Press Release Jan 30 2026
Filed with NSE · · 3 pages · English
Release
Strides Pharma Science Ltd on 6ix
In the deck
Earlier from Strides Pharma Science
- Press Release Oct 31 2025
- Intimation on Board Meeting scheduled for Oct 31, 2025
- Press Release Oct 17 2025
- Kenox Enters into Strategic Product Development Partnership with Strides
- Press Release Sep 08 2025
Later from Strides Pharma Science
- Strides Pharma Science Ltd Press Release Feb 05 2026
- Press Release (Revised) Feb 05 2026
- Press Release Mar 17 2026
- Press Release May 18 2026
- Strides Pharma Science Ltd Press Release Jun 27 2026
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science